Skip Navigation
Skip to contents

ICDM 2019

Main symposia

S3 Precision medicine in diabetes :
Do you feel like your T2D treatment is a "one-size-fits-all" protocol?		 09:00~10:40 / Friday 11 October
Convention hall B
Chairman:Yong Wook Cho, Hertzel C. Gerstein		 Overview

Organizers: Sung Hee Choi, Sang Soo Kim

This session titled, 'Precision medicine in diabetes' is a translational session that is designed to provide an evidence for clinicians and basic researchers to tailor type 2 diabetes therapy to an individual patient. For delivery of a targeted and personalized treatment for diabetic patients, integrative bioinformatic and clinical approaches, including proteomics and large-scale electric medical records, will be presented and discussed in this session. This session will be an essential step in helping to transform one-size-fits-all healthcare into a precision medicine based on a paradigm in diabetes.
Peter Rossing
Steno Diabetes Center, Denmark
 3-1Introduction to precision medicine and proteomics related precision medicine with diabetic nephropathy
Kwang Joon Kim
Yonsei University, Korea
 3-2From big data to precision medicine in diabetes
Daehee Hwang
Seoul National University, Korea
 3-3Ectopic fat proteome and diabetes
Meeyoung Park
Pusan National University, Korea
 3-4Data standardization with OMOP CDM for precision medicine
S7 DPP4I for Asian :
Does DPP4I work better for Asian, if Yes, why is so?		 13:20~15:20 / Friday 11 October
Convention hall B
Chairman:Moon-Gi Choi, Peter Rossing		 Overview

Organizers: Sang Yong Kim, Cheol-Young Park

After introduction of incretin-based therapy, the use of dipeptidyl peptidase(DPP)-IV inhibitor increased significantly over the past decade. Interestingly, the glucose-lowering efficacy of DPP-IV inhibitors or glucagon-like peptide-1 receptor agonists was reported to be greater in Asians than in non-Asians. This session titled, 'Does DPP4I work better for Asian, if yes, why is so?' is a clinical session that is designed to provide an opportunity for clinicians and basic researchers to discuss this unexplained clinical efficacy in Asians. Initially, three lecturers will give a talk about the effects of DPP-IV inhibitor according to the race, genomic differences and clinical responses. And then, four panelists will discuss why different responses have been made together with an audience. This session will be a cornerstone to understand more precise mechanism and action of incretin-based therapy.
Timothy Mark Earls Davis
University of Western Australia, Australia
 7-1Ethnic differences in the effects of DPP4I
Young Min Cho
Seoul National University, Korea
 7-2Genetic aspects on responses on incretin-based therapy
Jang Won Son
The Catholic University of Korea, Korea
 7-3Who is responder or non-responder of DPP4I?
Panel Discussion

Do you feel the population with diagnosed T2DM in Asia vs. ex-Asia is fundamentally homogenous in drug response and time to use drug?
- Sang Soo Kim (Pusan National University, Korea)
- Jin Hwa Kim (Chosun University, Korea)
What's the underlying mechanistic explanation for better glycemic efficacy in Asian populations?
- Hye Jin Yoo (Korea University, Korea)
- Kyung-Soo Kim (CHA University, Korea)
S12 Up-coming anti-diabetic medication :
Recent advance in drug for diabetes		 16:20~18:00 / Friday 11 October
Convention hall B
Chairman:Jeong Taek Woo, Vivian A. Fonseca		 Overview

Organizers: Sang Yong Kim, Cheol-Young Park, Jong Chul Won

This session titled, 'Recent advance in drug for diabetes' is a clinical session that is designed to provide an opportunity for clinicians and basic researchers to introduce newly developed and developing anti-diabetic agents. Over the years, many different classes of anti-diabetic medication have emerged with technological advances. However, continuous attempts have been made to investigate novel agents for the treatment in diabetes. In this session, four lecturers give a talk about various pharmacologic agents including oral and injectable agents from development to clinical practice. Through this session, we hope that many clinicians take this opportunity to keep up with the latest knowledge and directions of upcoming various ant-diabetic agents.
Michael Cummings
Portsmouth Hospitals NHS Trust, UK
 12-1Extension of SGLT2 inhibitor - dual inhibitor
Seung-Hwan Lee
The Catholic University of Korea, Korea
 12-2Long-acting DPP4 inhibitors
Stefano Del Prato
University of Pisa, Italy
 12-3GLP-1RA based co-agonist therapy
Carol H. Wysham
University of Washington, USA
 12-4New generation of insulin analogues
S17 Hearts in diabetes :
How to manage both diabetes and heart		 09:00~11:00 / Saturday 12 October
Convention hall B
Chairman:Min-Seon Kim, Timothy Mark Earls Davis

Organizers: Jung Hyun Noh, In-Kyung Jeong

This session titled, Hearts in diabetes, is a clinical session that is designed to provide an opportunity for clinicians and diabetes educators to understand interactions between diabetes and a heart disease. In this session, invited speakers will present new suggesting therapeutic strategies for prevention of CVD in diabetes and roles of newer and older anti-diabetic drugs in CVD.
Moon-Kyu Lee
Sungkyunkwan University, Korea
 17-1Strategies for prevention of cardiovascular disease in T2D
Barry H. Greenberg
University of California, USA
17-2 New drugs for treating heart failure - focus on patients with diabetes
Hertzel C. Gerstein
McMaster University, Canada
 17-3Using GLP-1 RAs to reduce CVD outcomes in people with diabetes
Vivian A. Fonseca
Tulane University, USA
 17-4The usefulness of pioglitazone to reduce cardiovascular risk
S22 New guidelines for T2D :
The new guidelines for type 2 diabetes		 13:30~15:00 / Saturday 12 October
Convention hall B
Chairman:Kyoil Suh, Barry H. Greenberg		 Overview

Organizers: Jung Hyun Noh, In-Kyung Jeong

This session titled, 'The new guidelines for type 2 diabetes,' is a clinical session that is organized to increase knowledge and promote better management of people with diabetes. This session includes the most current evidence-based recommendation of new guidelines in Korean Diabetes Association 2019, and updates in the management of dyslipidemia, obesity, and hypertension. Lectures presented will be of interest to clinically oriented physicians, researchers, epidemiologists, diabetes educators, and other health professionals.
Hyuk-Sang Kwon
The Catholic University of Korea, Korea
 22-1What's new in KDA guideline 2019
Eun-Jung Rhee
Sungkyunkwan University, Korea
 22-2Guideline updates in diabetes: dyslipidemia
Chong Hwa Kim
Sejong General Hospital, Korea
S22-3 Chong Hwa Kim
 22-3Guideline updates in diabetes: obesity
Sang Yong Kim
Chosun University, Korea
 22-4Guideline updates in diabetes: hypertension
  • Korean Diabetes Association
    101-2104, Lotte Castle President, 109
    Mapo-gu, Seoul, 04146, Korea

    E-mail : icdm@diabetes.or.kr

  • Congress Secretariat (The Within)
    5F, Samgyeong Bldg., #100-20, Yanghwa-ro, Mapo-gu, Seoul, Korea

    TEL : 82-2-6959-5333 FAX : . 82-70-8677-6333 E-mail : icdm@diabetes.or.kr